NL301224I2 - Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout - Google Patents

Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Info

Publication number: NL301224I2
Authority: NL; Netherlands
Prior art keywords: foslevodopa; foscarbidopa; optionally; combination; pharmaceutically acceptable
Prior art date: 2014-10-21

Application number

NL301224C

Other languages

English (en)

Other versions

NL301224I1 (nl

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-21

Filing date

2023-03-24

Publication date

2023-08-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301224(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2023-03-24 Application filed by Abbvie Inc filed Critical Abbvie Inc

2023-03-29 Publication of NL301224I1 publication Critical patent/NL301224I1/nl

2023-08-16 Publication of NL301224I2 publication Critical patent/NL301224I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NL301224C 2014-10-21 2023-03-24 Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout NL301224I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462066771P	2014-10-21	2014-10-21
PCT/US2015/056686 WO2016065019A1 (en)	2014-10-21	2015-10-21	Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (2)

Publication Number	Publication Date
NL301224I1 NL301224I1 (nl)	2023-03-29
NL301224I2 true NL301224I2 (nl)	2023-08-16

Family

ID=54478240

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301224C NL301224I2 (nl)	2014-10-21	2023-03-24	Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Country Status (37)

Country	Link
US (7)	US9446059B2 (nl)
EP (3)	EP3569587A1 (nl)
JP (6)	JP6567049B2 (nl)
KR (3)	KR102537018B1 (nl)
CN (4)	CN111494395B (nl)
AR (1)	AR102389A1 (nl)
AU (4)	AU2015335941B2 (nl)
BR (1)	BR112017008198B1 (nl)
CA (1)	CA2965379A1 (nl)
CY (2)	CY1121826T1 (nl)
DK (1)	DK3209302T3 (nl)
ES (1)	ES2739536T3 (nl)
FI (1)	FIC20230014I1 (nl)
FR (1)	FR23C1035I2 (nl)
HR (1)	HRP20191285T1 (nl)
HU (2)	HUE044115T2 (nl)
IL (3)	IL251829B (nl)
LT (2)	LT3209302T (nl)
LU (1)	LUC00304I2 (nl)
MX (2)	MX393568B (nl)
MY (1)	MY189519A (nl)
NL (1)	NL301224I2 (nl)
NO (1)	NO2023013I1 (nl)
PH (1)	PH12017500746B1 (nl)
PL (1)	PL3209302T3 (nl)
PT (1)	PT3209302T (nl)
RS (1)	RS58972B1 (nl)
RU (2)	RU2021103000A (nl)
SA (1)	SA521421115B1 (nl)
SG (1)	SG11201703170RA (nl)
SI (1)	SI3209302T1 (nl)
SM (1)	SMT201900376T1 (nl)
TR (1)	TR201908296T4 (nl)
TW (2)	TWI755257B (nl)
UA (1)	UA120437C2 (nl)
WO (1)	WO2016065019A1 (nl)
ZA (1)	ZA201702760B (nl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10258585B2 (en)	2014-03-13	2019-04-16	Neuroderm, Ltd.	DOPA decarboxylase inhibitor compositions
EP3116475B1 (en)	2014-03-13	2020-11-04	Neuroderm Ltd	Dopa decarboxylase inhibitor compositions
JP6567049B2 (ja) *	2014-10-21	2019-08-28	アッヴィ・インコーポレイテッド	カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
EP3445346A1 (en) *	2016-04-20	2019-02-27	AbbVie Inc.	Carbidopa and l-dopa prodrugs and methods of use
US11148999B2 (en)	2016-06-22	2021-10-19	MedChem Partners, LLC	Nitric oxide donors
WO2018154447A1 (en) *	2017-02-21	2018-08-30	Neuroderm Ltd	Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) *	2017-04-28	2018-11-01	Saniona A/S	Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en)	2017-11-16	2019-05-23	Orion Corporation	New use and pharmaceutical dosage forms
MX2020005366A (es)	2017-11-24	2020-08-13	H Lundbeck As	Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
CN110294789A (zh) *	2018-03-21	2019-10-01	海南大学	含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
SG11202101817UA (en)	2018-09-13	2021-03-30	Univ Canberra	Methods of inhibition
CN113015531A (zh) *	2018-11-15	2021-06-22	艾伯维公司	用于皮下施用的药物调配物
WO2020178810A1 (en) *	2019-03-04	2020-09-10	Neuroderm, Ltd.	Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11104697B2 (en)	2019-05-20	2021-08-31	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en)	2019-05-20	2021-09-28	H. Lundbeck A/S	Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en)	2019-05-20	2021-09-07	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en)	2019-05-20	2021-11-09	H. Lundbeck A/S	Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
CN113727974B (zh)	2019-05-21	2025-01-07	H.隆德贝克有限公司	用于治疗帕金森病的新儿茶酚胺前药
EP3972970A1 (en)	2019-05-21	2022-03-30	H. Lundbeck A/S	New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2020234277A1 (en)	2019-05-21	2020-11-26	H. Lundbeck A/S	Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
WO2020234275A1 (en)	2019-05-21	2020-11-26	H. Lundbeck A/S	New catecholamine prodrugs for use in the treatment of parkinson's diseases
US11331293B1 (en)	2020-11-17	2022-05-17	Neuroderm, Ltd.	Method for treatment of Parkinson's disease
US11844754B2 (en)	2020-11-17	2023-12-19	Neuroderm, Ltd.	Methods for treatment of Parkinson's disease
US11213502B1 (en)	2020-11-17	2022-01-04	Neuroderm, Ltd.	Method for treatment of parkinson's disease
EP4223288B1 (en)	2022-02-07	2024-03-06	Berlirem GmbH	Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en)	2023-04-14	2024-12-10	Neuroderm, Ltd.	Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3132171A (en) *	1962-06-18	1964-05-05	Strong Cobb Arner Inc	3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) *	1975-08-13	1977-04-05	Merck & Co., Inc.	Compositions and method of treating hypertension
DD230865B1 (de) *	1982-08-09	1987-05-20	Dresden Arzneimittel	Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4618484A (en)	1983-03-30	1986-10-21	Yale University	Composition and method for treatment of melanomas
US4508706A (en) *	1983-03-30	1985-04-02	Yale University	Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) *	1984-06-25	1989-12-14	Simes	Derivati di composti a struttura catecolamminica.
US4616484A (en)	1984-11-30	1986-10-14	Kysor Industrial Corporation	Vehicle refrigerant heating and cooling system
IT1200427B (it)	1985-03-22	1989-01-18	Afros Spa	Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja)	1987-09-18	1990-01-05	Banyu Pharmaceut Co Ltd	Ｌ‐ドーパ誘導体
IT1226727B (it)	1988-07-29	1991-02-05	Simes	Farmaci precursori della dopamina.
ATE118216T1 (de) *	1989-04-20	1995-02-15	Zambon Spa	Dopamin-medikament-vorstufe.
GB9102812D0 (en)	1991-02-11	1991-03-27	Enzymatix Ltd	Compounds
IT1255471B (it)	1992-07-30	1995-11-02	Zambon Spa	Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv)	1992-11-30	1992-11-30	Christer Nystroem	Laekemedel i dispersa system
AU1457299A (en) *	1997-11-12	1999-05-31	Ariad Pharmaceuticals, Inc.	Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en)	1998-01-20	2002-04-02	Glenn A. Meyer	Oral liquid compositions
US6204257B1 (en)	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) *	2002-05-29	2005-02-21	임팩스 라보라토리즈, 인코포레이티드	레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
JPWO2004000863A1 (ja)	2002-06-20	2005-10-20	日本水産株式会社	プロドラッグ、その医薬としての使用、およびその製法
WO2004052841A1 (en)	2002-12-06	2004-06-24	Xenoport, Inc.	Carbidopa prodrugs and uses thereof
EP1596808A4 (en)	2003-02-07	2007-04-04	Yissum Res Dev Co	L-DOPA AMID DERIVATIVES AND THEIR USE
DE602004031134D1 (de)	2003-08-29	2011-03-03	Transform Pharmaceuticals Inc	Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CN1845728B (zh) *	2003-08-29	2013-06-19	转化医药公司	包含左旋多巴和卡比多巴的药物组合物
JP2007509975A (ja)	2003-10-31	2007-04-19	アルザ・コーポレーシヨン	ギャバペンチン及びプレギャバリンの増加された吸収のための組成物及び投与形態物
MX339690B (es)	2004-06-04	2016-06-06	Xenoport Inc	Profarmacos de levodopa y sus composiciones y usos.
CN101023090B (zh)	2004-07-06	2013-03-27	雅培制药有限公司	Hiv蛋白酶抑制剂的前药
NZ569485A (en) *	2005-12-05	2011-06-30	Xenoport Inc	Levodopa prodrug mesylate, compositions thereof, and uses thereof
US20080051459A1 (en) *	2006-05-31	2008-02-28	Solvay Pharmaceuticals Gmbh	Long term 24-hour intestinal administration of levodopa/carbidopa
EP2037964A2 (en) *	2006-06-16	2009-03-25	Solvay Pharmaceuticals B.V.	Combination preparations comprising bifeprunox and l-dopa
US7709527B2 (en)	2006-12-21	2010-05-04	Xenoport, Inc.	Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
GB0713189D0 (en)	2007-07-06	2007-08-15	Proximagen Ltd	Amino acid derivatives
CA2714112C (en) *	2008-02-06	2015-08-11	Wockhardt Research Centre	Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
BRPI0912326A2 (pt)	2008-05-20	2015-10-06	Neurogesx Inc	análogos de acetaminofeno hidrossolúveis
US8193243B2 (en)	2009-05-19	2012-06-05	Neuroderm, Ltd.	Continuous administration of dopa decarboxylase inhibitors and compositions for same
US20130253056A1 (en)	2009-05-19	2013-09-26	Neuroderm, Ltd.	Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
WO2011056240A2 (en)	2009-11-09	2011-05-12	Xenoport, Inc.	Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8937151B2 (en)	2010-03-04	2015-01-20	University Of Notre Dame Du Lac	Gelatinase inhibitors and prodrugs
RU2740080C2 (ru)	2010-11-15	2021-01-11	Нейродерм Лтд	Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции
RU2570900C2 (ru)	2010-12-02	2015-12-20	Оно Фармасьютикал Ко., Лтд.	Новое соединение и его применение в медицине
BR112013014304A2 (pt)	2010-12-10	2016-07-19	Synagile Corp	composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
US8765189B2 (en) *	2011-05-13	2014-07-01	Howmedica Osteonic Corp.	Organophosphorous and multivalent metal compound compositions and methods
KR20130070371A (ko) *	2011-12-19	2013-06-27	울산대학교 산학협력단	퇴행성 신경질환 예방 또는 치료용 조성물
RU2018144700A (ru)	2013-03-13	2019-02-18	Неуродерм Лтд	Способ лечения болезни паркинсона
CN112521305B (zh)	2013-03-15	2023-04-25	苏州泰飞尔医药有限公司	治疗帕金森疾病的新型高穿透力药物及其药物组合物
JP6567049B2 (ja)	2014-10-21	2019-08-28	アッヴィ・インコーポレイテッド	カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
MA41377A (fr)	2015-01-20	2017-11-28	Abbvie Inc	Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
EP3445346A1 (en)	2016-04-20	2019-02-27	AbbVie Inc.	Carbidopa and l-dopa prodrugs and methods of use
US20190224153A1 (en)	2016-09-29	2019-07-25	Berlirem Gmbh	L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en)	2017-02-21	2018-08-30	Neuroderm Ltd	Dopa decarboxylase inhibitor compositions

2015
- 2015-10-21 JP JP2017521517A patent/JP6567049B2/ja active Active
- 2015-10-21 EP EP19164151.3A patent/EP3569587A1/en not_active Withdrawn
- 2015-10-21 KR KR1020177013734A patent/KR102537018B1/ko active Active
- 2015-10-21 WO PCT/US2015/056686 patent/WO2016065019A1/en not_active Ceased
- 2015-10-21 PT PT15791424T patent/PT3209302T/pt unknown
- 2015-10-21 BR BR112017008198-9A patent/BR112017008198B1/pt active IP Right Grant
- 2015-10-21 PL PL15791424T patent/PL3209302T3/pl unknown
- 2015-10-21 AR ARP150103412A patent/AR102389A1/es unknown
- 2015-10-21 HU HUE15791424 patent/HUE044115T2/hu unknown
- 2015-10-21 CN CN202010250040.7A patent/CN111494395B/zh active Active
- 2015-10-21 TW TW110101738A patent/TWI755257B/zh active
- 2015-10-21 ES ES15791424T patent/ES2739536T3/es active Active
- 2015-10-21 LT LTEP15791424.3T patent/LT3209302T/lt unknown
- 2015-10-21 CN CN202010250046.4A patent/CN111454290B/zh active Active
- 2015-10-21 HR HRP20191285TT patent/HRP20191285T1/hr unknown
- 2015-10-21 UA UAA201704815A patent/UA120437C2/uk unknown
- 2015-10-21 CN CN202010123543.8A patent/CN111362980B/zh active Active
- 2015-10-21 CN CN201580069519.8A patent/CN107206013A/zh active Pending
- 2015-10-21 EP EP15791424.3A patent/EP3209302B1/en active Active
- 2015-10-21 KR KR1020247023761A patent/KR20240113982A/ko active Pending
- 2015-10-21 CA CA2965379A patent/CA2965379A1/en not_active Abandoned
- 2015-10-21 DK DK15791424.3T patent/DK3209302T3/da active
- 2015-10-21 SG SG11201703170RA patent/SG11201703170RA/en unknown
- 2015-10-21 MY MYPI2017701367A patent/MY189519A/en unknown
- 2015-10-21 RU RU2021103000A patent/RU2021103000A/ru unknown
- 2015-10-21 SM SM20190376T patent/SMT201900376T1/it unknown
- 2015-10-21 EP EP22204022.2A patent/EP4186510A1/en active Pending
- 2015-10-21 SI SI201530761T patent/SI3209302T1/sl unknown
- 2015-10-21 MX MX2021003840A patent/MX393568B/es unknown
- 2015-10-21 KR KR1020237015051A patent/KR20230066484A/ko not_active Ceased
- 2015-10-21 AU AU2015335941A patent/AU2015335941B2/en active Active
- 2015-10-21 US US14/919,418 patent/US9446059B2/en active Active
- 2015-10-21 RU RU2017117413A patent/RU2743347C2/ru active
- 2015-10-21 MX MX2017005236A patent/MX381069B/es unknown
- 2015-10-21 RS RS20190854A patent/RS58972B1/sr unknown
- 2015-10-21 TR TR2019/08296T patent/TR201908296T4/tr unknown
- 2015-10-21 TW TW104134601A patent/TWI718999B/zh active
2016
- 2016-07-21 US US15/216,009 patent/US20160362431A1/en not_active Abandoned
2017
- 2017-04-19 ZA ZA2017/02760A patent/ZA201702760B/en unknown
- 2017-04-20 IL IL251829A patent/IL251829B/en active IP Right Grant
- 2017-04-20 SA SA521421115A patent/SA521421115B1/ar unknown
- 2017-04-21 PH PH12017500746A patent/PH12017500746B1/en unknown
- 2017-09-26 US US15/715,245 patent/US10174061B2/en active Active
2018
- 2018-12-05 US US16/210,996 patent/US10730895B2/en active Active
2019
- 2019-07-19 CY CY20191100771T patent/CY1121826T1/el unknown
- 2019-07-30 JP JP2019139442A patent/JP6750076B2/ja active Active
- 2019-08-23 IL IL268885A patent/IL268885B/en active IP Right Grant
2020
- 2020-05-04 US US16/866,400 patent/US11091507B2/en not_active Expired - Fee Related
- 2020-08-04 IL IL276493A patent/IL276493A/en unknown
- 2020-08-11 JP JP2020135560A patent/JP6932227B2/ja active Active
2021
- 2021-03-04 AU AU2021201414A patent/AU2021201414B2/en active Active
- 2021-07-16 US US17/378,321 patent/US20220153765A1/en not_active Abandoned
- 2021-08-16 JP JP2021132161A patent/JP2021183628A/ja active Pending
2022
- 2022-10-24 US US17/971,836 patent/US20230106081A1/en not_active Abandoned
2023
- 2023-02-20 HU HUS2300009C patent/HUS2300009I1/hu unknown
- 2023-03-07 CY CY2023010C patent/CY2023010I1/el unknown
- 2023-03-20 NO NO2023013C patent/NO2023013I1/no unknown
- 2023-03-24 NL NL301224C patent/NL301224I2/nl unknown
- 2023-03-31 FI FIC20230014C patent/FIC20230014I1/fi unknown
- 2023-04-03 LU LU00304C patent/LUC00304I2/fr unknown
- 2023-06-08 LT LTPA2023519C patent/LTC3209302I2/lt unknown
- 2023-08-04 AU AU2023210650A patent/AU2023210650A1/en not_active Abandoned
- 2023-09-29 FR FR23C1035C patent/FR23C1035I2/fr active Active
- 2023-10-06 JP JP2023174083A patent/JP7688087B2/ja active Active
2025
- 2025-05-21 JP JP2025084629A patent/JP2025118978A/ja active Pending
- 2025-09-25 AU AU2025238004A patent/AU2025238004A1/en active Pending

Also Published As

Publication number	Publication date
FR23C1035I1 (fr)	2023-12-08
TW201630924A (zh)	2016-09-01
JP2020189864A (ja)	2020-11-26
JP2025118978A (ja)	2025-08-13
DK3209302T3 (da)	2019-05-13
JP2017537066A (ja)	2017-12-14
US11091507B2 (en)	2021-08-17
FIC20230014I1 (fi)	2023-03-31
TWI755257B (zh)	2022-02-11
CN111494395A (zh)	2020-08-07
HUS2300009I1 (hu)	2023-03-28
MX393568B (es)	2025-03-24
AU2015335941B2 (en)	2021-04-01
US20220153765A1 (en)	2022-05-19
MX2017005236A (es)	2017-07-26
US10174061B2 (en)	2019-01-08
US9446059B2 (en)	2016-09-20
IL276493A (en)	2020-09-30
JP6932227B2 (ja)	2021-09-08
KR20230066484A (ko)	2023-05-15
RU2017117413A (ru)	2018-11-26
MX2021003840A (es)	2022-06-30
NZ730996A (en)	2024-04-26
CN107206013A (zh)	2017-09-26
ZA201702760B (en)	2022-05-25
AU2025238004A1 (en)	2025-10-16
EP3209302A1 (en)	2017-08-30
HRP20191285T1 (hr)	2019-10-18
PT3209302T (pt)	2019-07-19
CN111362980B (zh)	2022-10-18
LTPA2023519I1 (nl)	2023-06-26
LUC00304I2 (nl)	2025-09-22
US20180079762A1 (en)	2018-03-22
KR102537018B1 (ko)	2023-05-30
US20160362431A1 (en)	2016-12-15
RU2017117413A3 (nl)	2019-05-30
LTC3209302I2 (nl)	2025-10-10
PH12017500746B1 (en)	2021-12-15
CA2965379A1 (en)	2016-04-28
SG11201703170RA (en)	2017-05-30
AR102389A1 (es)	2017-02-22
NZ769153A (en)	2024-04-26
AU2015335941A1 (en)	2017-05-04
AU2021201414A1 (en)	2021-03-25
CN111454290B (zh)	2022-12-23
LT3209302T (lt)	2019-06-10
SMT201900376T1 (it)	2019-09-09
PH12017500746A1 (en)	2017-10-30
JP2023174770A (ja)	2023-12-08
EP3209302B1 (en)	2019-04-24
TR201908296T4 (tr)	2019-06-21
RU2743347C2 (ru)	2021-02-17
IL251829A0 (en)	2017-06-29
IL268885B (en)	2020-08-31
CY2023010I2 (el)	2023-06-09
EP4186510A1 (en)	2023-05-31
JP7688087B2 (ja)	2025-06-03
TWI718999B (zh)	2021-02-21
TW202131931A (zh)	2021-09-01
MX381069B (es)	2025-03-12
US20230106081A1 (en)	2023-04-06
JP2021183628A (ja)	2021-12-02
JP6567049B2 (ja)	2019-08-28
CN111362980A (zh)	2020-07-03
AU2021201414B2 (en)	2023-05-11
IL268885A (en)	2019-10-31
NO2023013I1 (no)	2023-03-20
SI3209302T1 (sl)	2019-06-28
BR112017008198B1 (pt)	2021-02-09
IL251829B (en)	2019-09-26
JP2019218356A (ja)	2019-12-26
FR23C1035I2 (fr)	2025-04-18
SA521421115B1 (ar)	2022-03-01
BR112017008198A2 (pt)	2017-12-26
ES2739536T3 (es)	2020-01-31
CN111454290A (zh)	2020-07-28
CY2023010I1 (el)	2023-06-09
HUE044115T2 (hu)	2019-10-28
CN111494395B (zh)	2024-06-21
US20160106765A1 (en)	2016-04-21
KR20170071599A (ko)	2017-06-23
US20190375770A1 (en)	2019-12-12
KR20240113982A (ko)	2024-07-23
RU2021103000A (ru)	2021-03-01
RS58972B1 (sr)	2019-08-30
NL301224I1 (nl)	2023-03-29
WO2016065019A1 (en)	2016-04-28
CY1121826T1 (el)	2020-07-31
PL3209302T3 (pl)	2019-10-31
US20200262852A1 (en)	2020-08-20
AU2023210650A1 (en)	2023-08-24
JP6750076B2 (ja)	2020-09-02
MY189519A (en)	2022-02-16
UA120437C2 (uk)	2019-12-10
US10730895B2 (en)	2020-08-04
EP3569587A1 (en)	2019-11-20

Publication	Publication Date	Title
NL301224I2 (nl)	2023-08-16	Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301329I2 (nl)	2025-09-09	Lazertinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301279I2 (nl)	2024-08-01	Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301342I2 (nl)	2025-11-10	Elafibranor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301341I2 (nl)	2025-10-02	eplontersen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301286I2 (nl)	2024-09-18	Danicopan, of een farmaceutisch aanvaardbaar zout ervan
NL301245I2 (nl)	2023-11-20	Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301161I2 (nl)	2022-04-06	zanubrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301155I2 (nl)	2022-02-23	abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301327I2 (nl)	2025-07-17	Belzutifan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder belzutifan
NL301128I2 (nl)	2021-10-25	Risdiplam of een farmaceutisch aanvaardbaar zout daarvan
NL301111I2 (nl)	2021-09-27	Entrectinib of een farmaceutisch aanvaardbaar zout daarvan
NO2025050I1 (no)	2025-11-28	Acalabrutinib or a pharmaceutically acceptable salt thereof, in combination with venetoclax optionally with or without obinutuzumab
NL301208I2 (nl)	2025-03-20	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301260I2 (nl)	2024-03-25	Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301149I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301344I2 (nl)	2025-11-10	lnavolisib of een farmaceutisch aanvaardbaar zout daarvan
NO2022009I1 (no)	2022-04-05	Lumasiran, optionally in the form of a salt
NL301238I2 (nl)	2023-10-04	Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
IL291922B1 (en)	2026-01-01	FAP-activated medical materials and related uses
NO2022046I1 (no)	2022-11-07	Berotralstat and pharmaceutically acceptable salts thereof
NL301263I2 (nl)	2024-08-01	elacestrant, desgewenst in de vorm van elacestrantdihydrochloride
NL301006I2 (nl)	2020-04-14	Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301326I2 (nl)	2025-07-31	imetelstat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301338I2 (nl)	2025-09-11	seladelpar of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder seladelpar-L-lysinedihydraat